Recombinant human kallikrein-1

DB19232InvestigationalProtein Based Therapies

Recombinant human kallikrein-1 is under investigation in clinical trial NCT01845064 (A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients).

Mechanism: Pharmacologically active on Kininogen-1
Curator reviewed
Also known as: Kallikrein-1, recombinant human · Recombinant human tissue kallikrein-1
Code names: DM-199

Resolves to

Compound

UNIIM5EX3P489FCAS389069-73-2

Targets

P01042KNG1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Recombinant human kallikrein-1, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account